CRISPR Therapeutics AG (CRSP)
| Market Cap | 5.34B |
| Revenue (ttm) | 38.34M |
| Net Income (ttm) | -488.30M |
| Shares Out | 95.30M |
| EPS (ttm) | -5.58 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,948,585 |
| Open | 51.49 |
| Previous Close | 51.58 |
| Day's Range | 51.16 - 56.01 |
| 52-Week Range | 30.04 - 78.48 |
| Beta | 1.73 |
| Analysts | Buy |
| Price Target | 71.50 (+27.7%) |
| Earnings Date | Nov 10, 2025 |
About CRSP
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company’s CRISPR/Cas9 is a revolutionary technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, a... [Read more]
Financial Performance
In 2024, CRISPR Therapeutics AG's revenue was $37.31 million, a decrease of -89.95% compared to the previous year's $371.21 million. Losses were -$366.25 million, 138.4% more than in 2023.
Financial StatementsAnalyst Summary
According to 19 analysts, the average rating for CRSP stock is "Buy." The 12-month stock price target is $71.5, which is an increase of 27.70% from the latest price.
News
Meet the Beaten-Down Biotech Stock Cathie Wood Loves That Wall Street Says May Soar 50%
Cathie Wood aims to identify innovators and invest in them early in their stories. Wood has been regularly adding to her position in this stock, and it's one of her top holdings.
The Best Stocks to Buy With $1,000 Right Now
It may be the spawn of a company that faded into irrelevancy, but GE Vernova is thriving as a standalone outfit. Most investors may not appreciate just how long it takes CRISPR Therapeutics to complet...
3 Mid-Cap Growth Stocks That Have Mammoth Long-Term Potential
Mid-cap stocks can come with risks, but also a ton of upside in the long run. The stocks listed here offer exciting growth opportunities across multiple industries.
Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon.
Eli Lilly has advanced in the triple-digits over three years, thanks to its weight loss drug portfolio. The following two biotech companies, due to the potential of their late-stage candidates, also c...
1 Underrated Stock That Could Soar by 58%, According to Wall Street
CRISPR Therapeutics' sole approved product doesn't generate much sales yet. It does have some pipeline candidates that could make progress over the next year.
CRISPR Therapeutics Post Q3 Earnings: Testing Investor Patience, But Still A Buy
CRISPR Therapeutics AG remains a pioneering gene editing company, with Casgevy's slow commercial ramp and robust pipeline driving long-term potential. Despite Casgevy's $2.2M list price and broad appr...
ARK Sold Almost 400,000 Shares of CRISPR Therapeutics. Is Cathie Wood Worried?
Ark Investment sold 395,617 shares worth about $25 million. It represents a minor change in its 13F assets under management (AUM).
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results
-Positive Phase 1 data for CTX310 ® presented in a late-breaking presentation at the American Heart Association (AHA) Scientific Sessions and simultaneously published in The New England Journal of Med...
CRISPR gene therapy slashes 'bad' cholesterol, triglycerides by half in small study
A single infusion of CRISPR Therapeutics' experimental gene therapy was safe and reduced levels of harmful LDL cholesterol and triglycerides by half in four people taking the highest dose, raising hop...
CRISPR Therapeutics Announces Positive Phase 1 Clinical Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and Lipid Lowering
-Data presented in a late-breaking presentation at the American Heart Association (AHA) Scientific Sessions 2025- -Phase 1 clinical data for CTX310® demonstrate robust, dose-dependent reductions in ci...
Prediction: 2 Stocks That Will Be Worth More Than SoundHound AI 2 Years From Now
SoundHound AI's conversational AI solutions are seeing rapid adoption among enterprises. CRISPR Therapeutics' Casgevy is targeting a multibillion-dollar opportunity.
2 Soaring Cathie Wood Stocks to Buy and Hold
Cathie Wood, the chief executive officer of Ark Invest, can be somewhat of a polarizing figure, with some research indicating that her investment firm's actively managed exchange-traded funds (ETFs) h...
New to Growth Stocks? Here's 1 Every Investor Should Have on Their Radar.
Investing in modestly sized growth stocks can lead to significant returns, but oftentimes it requires taking on a fair bit of risk and being willing to wait at least a few years for a payoff. There ar...
4 Healthcare Stocks to Buy Now
Healthcare stocks have struggled since interest rates began climbing in 2022. Rising yields pulled capital away from speculative biotech and drug development, pushing valuations lower even as research...
CRISPR Therapeutics Presents New Preclinical Data for CTX460™ Demonstrating In Vivo Gene Correction of Alpha-1 Antitrypsin Deficiency (AATD) Utilizing Novel SyNTase™ Editing Platform
-Preclinical data presented at the European Society of Gene and Cell Therapy (ESGCT) highlight a potential best-in-class profile-
Healthcare Stocks Are Rising: Here Are 2 With Even More Upside Ahead
On Sept. 30, Pfizer announced a deal with the U.S. government that will allow the pharmaceutical leader to avoid President Donald Trump's tariffs for three years in exchange for slashing the prices of...
CRISPR Therapeutics to Present Preclinical Data on Alpha-1 Antitrypsin Deficiency (AATD) Utilizing Novel SyNTase Gene Editing Technology at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress
ZUG, Switzerland and BOSTON, Oct. 01, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious disea...
Got $200? 2 Healthcare Stocks to Buy and Hold Forever
You don't have to invest a fortune to get involved in an industry that could offer your portfolio growth along with safety. I'm talking about the field of healthcare, specifically companies that devel...
Could This Beaten-Down Stock Help You Become a Millionaire?
Becoming a millionaire through stock investing is possible, but it requires patience, discipline, and the acumen to make informed investment choices. Not every company can generate the kind of returns...
Crispr Therapeutics: Why Stock Fell On Q2 Earnings, And Why We're Now Back On Track
Crispr Therapeutics AG remains undervalued despite recent stock volatility and slow Casgevy commercial uptake, with long-term potential intact. Casgevy's strong clinical data and broad approvals are t...
Cathie Wood Goes Bargain Hunting: She Just Bought 2 Stocks That Wall Street Thinks Will Climb 50% and 190%
Cathie Wood is known for seizing opportunities. The founder of Ark Invest doesn't worry when one of the stocks she's invested in drops, and instead, she looks at the movement as a chance to increase h...
CRISPR Therapeutics to Present Late-Breaking Data at the American Heart Association (AHA) Scientific Sessions 2025
ZUG, Switzerland and BOSTON, Sept. 09, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious dise...
Biotech Sector Shows No Signs of Slowing. 3 Stocks That Make the Grade.
Last week, the SPDR S&P Biotech ETF surged 6%.
CRISPR Therapeutics AG (CRSP) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
CRISPR Therapeutics AG (NASDAQ:CRSP) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 8:30 AM EDT Company Participants Samarth Kulkarni - CEO & Chairman Conference Call Parti...
CRISPR Therapeutics AG (CRSP) Presents at H.C. Wainwright 27th Annual Global Investment Conference Transcript
CRISPR Therapeutics AG (NASDAQ:CRSP) H.C. Wainwright 27th Annual Global Investment Conference September 8, 2025 4:30 PM EDT Company Participants Raju Prasad - Chief Financial Officer Conference Call ...